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Biomonitoring of phthalate metabolites has 
identified virtually ubiquitous human expo­
sure internationally and for all age groups 
(Centers for Disease Control and Prevention 
2005). Phthalate metabolites have been 
detected in many body tissues including urine, 
blood, semen, amniotic fluid, and breast milk 
(National Research Council 2008). Despite 
the relatively rapid clearance of phthalate 
metabolites, urine phthalate biomarker meas­
urements are relatively stable over periods of 
days to months (Adibi et al. 2008; Hauser 
et al. 2004; Teitelbaum et al. 2008), probably 
because exposure sources and patterns of usage 
of phthalate­containing products are com­
mon and fairly consistent (Hauser et al. 2004; 
Teitelbaum et al. 2008).
At least 10 different phthalates are used 
commercially as plasticizers, solvents, anti­
foam agents, or alcohol denaturants. High­
molecular­weight phthalates (HMWP) [e.g., 
di(2­ethylhexyl) phthalate (DEHP)] can be 
found in tubing, vinyl flooring, and wall 
covering. Low­molecular­weight phthalates 
(LMWP) (e.g., diethyl phthalate) more com­
monly can be present in personal care prod­
ucts (fragrances, shampoo, cosmetics, and 
nail polish). Phthalates are also found as both 
inert and active ingredients in some pesticide 
formulations. Human exposure to phthalates 
can occur through inhalation, ingestion, and 
dermal contact. Once absorbed, they are rap­
idly metabolized to monoesters, and the high­
molecular­weight monoesters can undergo 
further oxidation to form oxidative metabo­
lites (National Research Council 2008).
Some phthalates have been regulated in 
consumer products in Europe and the United 
States (California Safe Cosmetics Act 2005; 
Consumer Product Safety Improvement Act 
2008; Directive 2005/84/EC of the European 
Parliament and of the Council 2005). The 
regulations in the United States are aimed 
at reducing childhood exposure to DEHP, 
dibutyl phthalate (DBP), and benzyl butyl 
phthalate by regulating their presence in 
bath toys or other small plastic toys that can 
be placed in the mouth easily. However, in 
some circumstances, these phthalates have 
been replaced with others (e.g., di­isononyl­ 
or di­isodecyl­phthalates for DEHP) that 
remain unregulated. Regulatory action was 
based mainly on studies of male reproductive 
toxicity in both animals and humans, which 
is related to testicular­based androgen insuf­
ficiency (National Research Council 2008).
Antagonistic effects of phthalates on the 
thyroid gland in vivo and thyroid tissue in vitro 
have been reported (Hinton et al. 1986; Pereira 
et al. 2007; Poon et al. 1997; Price et al. 1988; 
Sugiyama et al. 2005). DBP has been associ­
ated with a dose­dependent decrease in circu­
lating triiodothyronine and thyroxine (T4) in 
rats (O’Connor et al. 2002). In humans, low 
serum free T4 was associated with high uri­
nary concentrations of monobutyl phthalate (a 
metabolite of DBP) (Huang et al. 2007) and of 
mono(2­ethylhexyl) phthalate (a metabolite of 
DEHP) during pregnancy (Meeker et al. 2007). 
Recently, phthalate exposure in childhood was 
associated with attention deficit hyperactivity 
disorder (ADHD) in a cross­  sectional study of 
Korean school children between the ages of 8 
and 11 years (Kim et al. 2009).
Objective
The objective of the Mount Sinai Children’s 
Environmental Health Center is to investi­
gate the role of prenatal toxicant exposures 
on childhood growth and neurodevelopment. 
We recently reported a relationship between 
prenatal maternal concentrations of phthalate 
metabolites and altered neonatal behavior, 
specifically in the orientation and motor scales 
and their overall quality of alertness, exam­
ined within 5 days of delivery (Engel et al. 
2009). The consequences of prenatal expo­
sure on neurobehavioral development during 
childhood have not previously been reported. 
Therefore, we examined these relationships 
in a subset of our cohort who returned for 
follow­up visits between 4 and 9 years of age.
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Ba c k g r o u n d: Experimental and observational studies have reported biological consequences of 
phthalate exposure relevant to neurodevelopment.
oB j e c t i v e: Our goal was to examine the association of prenatal phthalate exposure with behavior 
and executive functioning at 4–9 years of age.
Me t h o d s : The Mount Sinai Children’s Environmental Health Study enrolled a multiethnic pre-
natal population in New York City between 1998 and 2002 (n = 404). Third-trimester maternal 
urines were collected and analyzed for phthalate metabolites. Children (n = 188, n = 365 visits) were 
assessed for cognitive and behavioral development between the ages of 4 and 9 years.
re s u l t s: In multivariate adjusted models, increased loge concentrations of low molecular weight 
(LMW) phthalate metabolites were associated with poorer scores on the aggression [β = 1.24; 95% 
confidence interval (CI), 0.15– 2.34], conduct problems (β = 2.40; 95% CI, 1.34–3.46), attention 
problems (β = 1.29; 95% CI, 0.16– 2.41), and depression (β = 1.18; 95% CI, 0.11–2.24) clinical 
scales; and externalizing problems (β = 1.75; 95% CI, 0.61–2.88) and behavioral symptom index 
(β = 1.55; 95% CI, 0.39–2.71) composite scales. Increased loge concentrations of LMW phthalates 
were also associated with poorer scores on the global executive composite index (β = 1.23; 95% CI, 
0.09–2.36) and the emotional control scale (β = 1.33; 95% CI, 0.18– 2.49).
co n c l u s i o n: Behavioral domains adversely associated with prenatal exposure to LMW phthalates 
in our study are commonly found to be affected in children clinically diagnosed with conduct or 
attention deficit hyperactivity disorders.
key w o r d s : attention deficit hyperactivity disorder, BASC, BRIEF, environmental exposure, 
phthalate. Environ Health Perspect 118:565–571 (2010).  doi:10.1289/ehp.0901470 [Online 
28 January 2010]Engel et al.
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Methods
Enrollment of birth cohort and child follow-up. 
The Mount Sinai Children’s Environmental 
Health study enrolled a prospective multiethnic 
cohort of primiparous women with singleton 
pregnancies. Women presented for prenatal 
care either at the Mount Sinai Diagnostic and 
Treatment Center, which serves the predomi­
nantly minority East Harlem population, or at 
one of two private practices on the Upper East 
Side of Manhattan. Four hundred seventy­
nine mother–infant pairs were successfully 
recruited. Women delivered at the Mount 
Sinai Medical Center between May 1998 
and July 2001 (Berkowitz et al. 2003, 2004). 
Seventy­five women were excluded for reasons 
detailed elsewhere (Engel et al. 2007), includ­
ing extreme prematurity; the final cohort was 
404 women for whom birth data were avail­
able. Questionnaires were administered to 
participants during the third trimester of preg­
nancy to obtain information on sociodemo­
graphic characteristics, medical history, and 
lifestyle factors. A maternal spot urine sample 
was obtained between 25 and 40 weeks’ ges­
tation (mean, 31.2 weeks). Delivery charac­
teristics and birth outcomes were obtained 
from a perinatal database maintained within 
the Mount Sinai Department of Obstetrics, 
Gynecology and Reproductive Science.
Women were invited to return for three 
follow­up visits when their children were 
between 4 and 9 years of age. We attempted 
to complete interviews in each of these three 
periods: 4.5–5.5 years; 6–6.5 years; and 
7–9 years. The number of visits per child 
ranged from one to three (approximately 
40% came once, 26% came twice, 34% came 
three times), totaling 365 visits completed 
by 188 children (Table 1). Among these 
were five children who were not included in 
the original birth cohort analysis (n = 404) 
because they were not delivered at Mount 
Sinai (and therefore birth outcome informa­
tion was unavailable), although they returned 
for follow­up study visits. The study was 
approved by the Institutional Review Board 
of the Mount Sinai School of Medicine; par­
ticipants provided written informed consent 
before the study, and children ≥ 7 years of 
age provided assent.
Phthalate metabolite measurements. 
Sufficient maternal urine remained for 
177 women to measure phthalate metabolite 
concentrations. Maternal urine samples were 
analyzed at the Centers for Disease Control 
and Prevention for 10 phthalate metabolites. 
Methods and quality control procedures have 
been described previously (Kato et al. 2005; 
Silva et al. 2008). To limit the number of sta­
tistical tests performed, phthalate metabolites 
were grouped into two categories defined by 
the molecular weight of the monoesters [high 
(> 250 Da) and low (< 250 Da)], as they have 
similar biologic activity as their parent diesters 
and come from similar environmental sources 
(Wolff et al. 2008). The concentrations, by 
molar sum and individual metabolite, have 
been previously reported (Wolff et al. 2008). 
To account for urine dilution, we included log­
creatinine in models where metabolites were 
considered continuous, log­transformed vari­
ables. When metabolites were considered in 
tertiles, creatinine­based concentrations (micro­
moles per gram creatinine) were used to derive 
tertile cut points.
Behavior and executive functioning out-
comes. At each visit, mothers completed the 
parent­report forms of the Behavior Rating 
Inventory of Executive Function (BRIEF), and 
the Behavior Assessment System for Children­
Parent Rating Scales (BASC­PRS). These are 
standardized instruments commonly used in 
both research and clinical environments that 
have been validated in diverse samples and 
have known psychometric properties (Gioia 
et al. 2000; Reynolds and Kamphaus 1998). 
Mothers also provided current sociodemo­
graphic and other information on their chil­
dren. Questionnaires were available in both 
Spanish and English.
The BRIEF is an 86­item questionnaire 
designed to assess executive cognitive func­
tion in children 5–18 years of age. Executive 
functions are used to achieve goals that require 
planning and holding in memory a multi­
step sequence of thoughts or actions, to moni­
tor and control attention and emotion, to 
inhibit inappropriate behaviors, and to formu­
late mental models based on life experiences 
(Pennington et al. 1997). The BRIEF is com­
posed of eight clinical scales:
•	Inhibit—the	ability	to	control	impulses
•	Shift—the	ability	to	transition	between	
  situations
•	Emotional	control—the	ability	to	modulate	
emotional responses
•	Initiate—the	ability	to	begin	a	task
•	Working	memory—the	ability	to	retain	
information for task completion
•	Plan/organize—the	ability	to	anticipate	
future events, set goals, and develop a system­
atic plan of action
•	Organization	of	materials—the	ability	keep	
workspace orderly
•	Monitor—the	ability	to	asses	personal	per­
formance and to register the effect of one’s 
own behavior on others.
Table 1. Comparison of children followed up with original birth cohort population, Mount Sinai Medical 
Center, New York, New York, USA, 1998–2008.
Original birth cohort 
(n = 404)
Children followed up 
(n = 188)a
Population characteristics  n Percent n Percent p-Value 
Maternal age at enrollment (years) 0.04
< 20 142 35.2 58 30.9
20–24 132 32.7 62 33.0
25–29 44 10.9 29 15.4
≥ 30 86 21.3 39 20.7
Maternal race/ethnicity 0.92
White 86 21.3 38 20.2
Black 112 27.7 55 29.3
Hispanic 200 49.5 92 48.9
Other 6 1.5 3 1.6
Maternal education 0.09
< High school 118 29.2 46 24.5
High school 83 20.5 40 21.3
Some college 103 25.5 57 30.3
≥ College degree 100 24.8 45 24.0
Marital status at enrollment 0.10
Married 117 29.0 47 25.0
Living with father of child 98 24.3 42 22.3
Single/divorced/widowed 189 46.8 99 52.7
Smoke during pregnancy (ever) 67 16.6 31 16.9 0.86
Alcohol during pregnancy (ever) 59 14.9 28 15.6 0.78
LMWP (μM/L) (n = 177) 2.24b 0.90–5.65c 1.88b 0.83–4.59c 0.15
HMWP (μM/L) (n = 177) 0.43b 0.22–0.91c 0.43b 0.18–0.90c 0.54
Mother is primary caretaker 151 83.0
Breast-feeding of child (months)
< 1 70 40.0
1–4 38 21.7
> 4 67 38.3
Retention at each interview period (years)
4.5–5.5 102 54.3
6–6.5 113 60.1
7–9 146 77.7
aIncludes five children who were not included in the birth cohort analyses because they were not born at Mount Sinai. 
bMedian. cInterquartile range. Prenatal phthalates and childhood behavior
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These eight scales generate two broad 
indexes: Behavioral Regulation Index (BRI) 
and Metacognition Index (MI). An over­
all score, the Global Executive Composite 
(GEC), is obtained from the raw scores for 
the MI and BRI. For all scales, higher scores 
indicate worse executive functioning.
The BASC (Reynolds and Kamphaus 
1998) is designed to evaluate problematic 
behaviors in children and adolescents 2.5–18 
years of age. The BASC­PRS includes nine 
clinical scales to assess a child’s adaptive and 
problem behaviors in home and community 
settings. Parents respond to 130 items on a 
4­point scale that ranges from never to almost 
always. Externalizing problems is a composite 
scale derived from the hyperactivity (includ­
ing both hyperactivity and impulsivity items), 
aggression, and conduct problems scale items. 
Internalizing problems is a composite of the 
anxiety, depression, and somatization scale 
items. Three additional scales are attention 
problems, atypicality, and withdrawal. The 
adaptive behavior skills composite com­
bines information from the adaptability, 
social skills, and leadership scale items. The 
Behavioral Symptoms Index (BSI) is the api­
cal summary score that assesses the overall 
level of behavioral functioning. For the clini­
cal and composite scales, higher scores indi­
cate more problem behaviors. For the adaptive 
scales, lower scores indicate more problem 
behaviors. Thresholds delineating an at­risk 
or clinically significant scaled score have been 
established. For the clinical scales, the at­risk 
threshold is a T­score of 60–69, and the clini­
cally significant threshold is a T­score of ≥ 70. 
For the adaptive scales, the at­risk threshold is 
a T­score of 31–40, and the clinically signifi­
cant threshold is a T­score of ≤ 30. 
The BRIEF and BASC are standardized 
for age and sex and provide T­scores with a 
mean (± SD) of 50 ± 10. Both instruments 
have good internal consistency, test–retest 
reliability, content and construct validity, and 
convergent discriminate validity (Pizzitola 
2002; Reynolds and Kamphaus 1998).
Statistical analyses. We analyzed data using 
SAS version 9.2 (SAS Institute Inc., Cary, 
NC). Both the BASC and BRIEF include 
standard validity scales to identify problematic 
observations. For the BASC, the Infrequency 
Index (F) includes items that are rarely 
endorsed when the assessment is valid and can 
indicate an excessively negative evaluation of 
the child, a failure to follow instructions, ran­
dom responding, or difficulty reading. Raw 
F­scores on the BASC Parent Rating Scales 
(PRS) can vary from 0 to 6, with higher scores 
warranting closer review. All surveys with 
F­scores greater than 3 (n = 2 surveys) were 
excluded a priori, because the validity of these 
surveys is questionable. In the case of F­scores 
of 2 (n = 15 surveys) or 3 (n = 10 surveys), a 
committee of three investigators reviewed the 
child’s records for parental reports of clinically 
diagnosed or treated psychiatric or neurologic 
problems and current or past usage of psycho­
tropic medications. The reviewers also looked 
for evidence of invalid, inconsistent, or unusual 
response patterns. After review, we excluded 
12 surveys for the following reasons: language 
difficulty (n = 2), evidence of random respond­
ing (n = 7), and overly negative or unrealistic 
evaluation of child’s behavior (n = 3). We did 
not exclude surveys with F­scores of 2 or 3 if 
the parent reported negative behaviors and the 
child was currently receiving treatment for or 
had previously been diagnosed with psychiatric 
or neuro  logic problems.
Children were invited to return for three 
visits, but compliance varied. For children 
who returned for more than one visit, we took 
the average of scale­specific T­scores. Because 
T­scores are age­standardized, no additional 
adjustment for child age in the model was 
included. We conducted multivariate analy­
ses using PROC GLM (SAS Institute Inc.). 
Independent variables were chosen based on 
their relationships with the outcomes of inter­
est, as well as their correlation with phthalate 
metabolite concentrations. Given that phtha­
lates are reported to be reproductive toxicants 
and exhibit hormonal antagonism, we a priori 
hypothesized that there may be sex interac­
tions. Therefore, we first examined the signifi­
cance of sex–phthalate interactions (α = 0.10), 
before considering sex as a possible confounder. 
We used a backward elimination method to 
obtain the most parsimonious model, elimi­
nating covariates that did not change the esti­
mate of the main effect by at least 10%. All 
models were adjusted for urinary creatinine 
concentration. As a first step, effects of phtha­
late metabolite concentration were examined 
using creatinine­based tertiles. Because the 
trend in the least­square means across the ter­
tiles supported a linear effect, the final models 
were based on the loge­linear term of phtha­
late metabolite concentrations (Figure 1). 
Alternative analytic approaches (e.g., repeated 
measures analyses) were examined to evaluate 
the consistency of our findings. In these mod­
els, the coefficient for visit did not significantly 
differ from zero, suggesting that scores did not 
systematically vary across visits. Additionally, 
the phthalate effects were very similar compar­
ing the average T­scores to the repeated meas­
ures models; thus, our final models were based 
on the average score.
Figure 1. Adjusted mean BASC T-score and 95% CIs for aggression (A), attention problems (B), conduct problems (C), depression (D), externalizing problems (E), 
and BSI (F), plotted at the median creatinine-based phthalate biomarker concentration by tertile of exposure to assess linearity in dose response. LSMEAN, least-
square mean. Means were adjusted for race, sex, educational level of the primary caretaker, and marital status of the primary caretaker. All affected domains 
appeared to be monotonically associated with phthalate biomarker level, with the exception of attention problems, which appeared to plateau at 2 µM. 
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Results
There were slight differences in the character­
istics of women who returned for follow­up 
versus the original birth cohort (Table 1). 
Compared with the original birth cohort, the 
women who returned for follow­up tended 
to be those who were slightly older at the 
time of enrollment. However, the racial/eth­
nic mix, educational attainment, marital sta­
tus, and median urinary concentrations of 
the metabolites of low and high molecular 
phthalates were similar. Among the children 
followed up, 54% were boys, 75% of the chil­
dren spoke only English at home, and 83% 
of mothers were the child’s primary caretaker. 
Those with other caretakers generally reported 
either father or grandmother.
HMWP were not associated with most 
of the BASC or BRIEF domains, except that 
increased log­HMWP was associated with 
poorer scores on the adaptability scale of the 
BASC [β = –1.33; 95% confidence interval 
(CI), –2.53 to –0.14]. 
Low molecular weight phthalate (LMWP) 
concentrations were strongly related to a 
number of clinical and composite scales 
(Table 2). In multivariate adjusted models, 
each log­unit increase in LMWP metabo­
lite concentrations was associated with a 
1.24­point increase on the aggression scale 
[95% confidence interval (CI), 0.15–2.34], 
a 1.29­point increase on the attention prob­
lems scale (95% CI, 0.16–2.41), a 2.4­point 
increase on the conduct problems scale (95% 
CI, 1.34–3.46), and a 1.18­point increase on 
the depression scale (95% CI, 0.11–2.24). 
Although the associations between urinary 
concentrations of phthalate metabolites and 
the adaptive scales did not reach conventional 
levels of statistical significance, there was a 
consistent pattern of poorer adaptive profiles 
with increasing metabolite concentrations. 
This pattern was also evident in the composite 
Adaptive Skills Index (β = –0.98; 95% CI, 
–2.05 to 0.09). However, the associations 
were stronger between phthalate metabolite 
concentrations and externalizing problems 
(β = 1.75; 95% CI, 0.61–2.88) and the 
BSI (β = 1.55; 95% CI, 0.39–2.71). These 
effects were not modified by the child’s sex. 
Using creatinine­corrected tertiles of phtha­
late exposure, we plotted the tertile­specific 
adjusted mean T­score at the median micro­
molar concentration of metabolites of LMWP 
to examine the shape of the dose–response 
relationship (Figure 1). Consistent with the 
log­linear models, the strongest linear trends 
were demonstrated for conduct problems 
and externalizing problems; however, all 
scales demonstrated monotonically increas­
ing LSMEANS, with the exception of the 
Table 2. Prenatal metabolite concentrations of 
LMWP and the BASC in a multiethnic birth cohort, 
Mount Sinai Medical Center, New York, New York, 
USA, 1998–2008.a
BASC domain
β per loge-unit increase 
in LMWP (95% CI)
Clinical scales
Aggression 1.24 (0.15 to 2.34)
Anxiety 0.78 (–0.46 to 2.02)
Attention problems 1.29 (0.16 to 2.41)
Atypicality 0.95 (–0.03 to 1.92)
Conduct problems 2.40 (1.34 to 3.46)
Depression 1.18 (0.11 to 2.24)
Hyperactivity 1.03 (–0.21 to 2.28)
Somatization 0.36 (–0.85 to 1.56)
Withdrawal 0.46 (–0.66 to 1.58)
Adaptive scales
Adaptability –1.08 (–2.14 to –0.02)
Leadership –0.88 (–2.04 to 0.28)
Social skills –1.04 (–2.14 to 0.05)
Composite scales
Externalizing problems 1.75 (0.61 to 2.88)
Internalizing problems 0.99 (–0.22 to 2.20)
Adaptive skills –0.98 (–2.05 to 0.09)
BSI 1.55 (0.39 to 2.71)
aIncludes subjects with F-scores of 0–3 and adjusted 
for race, sex, educational level of the primary caretaker, 
marital status of the primary caretaker, and urinary crea-
tinine. All scales except conduct problems and leadership 
included 171 subjects. Conduct problems and leadership 
items are queried only on the 6- to 11-year BASC-PRS, so 
the number of subjects with these scales was 159.
Table 4. Comparison of betas from metabolite-specific models to the LMWP molar sum for the BASC 
among boys in a multiethnic birth cohort, Mount Sinai Medical Center, New York, New York, USA, 
1998–2008.
BASC domain LMWP sum MBP MEP MiBP MMP
Clinical scales
Aggression 1.24* 1.28* 0.91 –0.12 0.53
Anxiety 0.78 –0.04 0.79 –0.25 1.46
Attention problems 1.29* 0.92 1.28* 0.66 1.66*
Atypicality 0.95 0.83 0.74 0.53 1.13
Conduct problems 2.40* 0.92 1.85* 0.23 1.18
Depression 1.18* 0.78 0.97* 0.29 2.07*
Hyperactivity 1.03 1.34 0.83 0.85 0.61
Somatization 0.36 0.84 0.11 1.04 1.06
Withdrawal 0.46 –0.10 0.44 –0.01 –0.84
Adaptive scales
Adaptability –1.08* –0.92 –0.97* –1.32* –1.19
Leadership –0.88 –0.54 –0.84 –1.30 –1.46
Social skills –1.04 –0.75 –0.97 –0.93 –0.92
Composite scales
Externalizing problems 1.75* 1.36* 1.33* 0.33 0.70
Internalizing problems 0.99 0.66 0.80 0.46 1.99*
Adaptive skills –0.98 –1.18 –0.79 –1.17 –0.85
BSI 1.55* 1.23 1.32* 0.47 1.77*
Abbreviations: MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate. Includes subjects with F-scores of 0–3 and 
adjusted for race, sex, educational level of the primary caretaker, marital status of the primary caretaker, and urinary 
creatinine. 
*p ≤ 0.05.
Table 3. Prenatal metabolite concentrations of LMWP and the BASC among boys in a multiethnic birth 
cohort, Mount Sinai Medical Center, New York, New York, USA, 1998–2008.a
BASC domain
β per LMWP loge-unit 
increase in boys (95% CI)
β per LMWP loge-unit 
increase in girls (95% CI)
p-Value for 
interaction
Clinical scales
Aggression 1.46 (0.17 to 2.76) 0.86 (–0.80 to 2.52) 0.02
Anxiety 0.73 (–0.73 to 2.19) 0.88 (–1.00 to 2.75) 0.42
Attention problems 1.55 (0.22 to 2.88) 0.83 (–0.87 to 2.54) 0.16
Atypicality 0.36 (–0.78 to 1.50) 1.96 (0.49 to 3.42) 0.89
Conduct problems 2.79 (1.55 to 4.03) 1.70 (0.09 to 3.31) 0.02
Depression 1.20 (–0.06 to 2.46) 1.14 (–0.47 to 2.76) 0.19
Hyperactivity 1.39 (–0.08 to 2.85) 0.42 (–1.46 to 2.30) 0.04
Somatization 0.58 (–0.84 to 2.00) –0.03 (–1.86 to 1.79) 0.39
Withdrawal 0.34 (–0.98 to 1.65) 0.67 (–1.02 to 2.36) 0.85
Adaptive scales
Adaptability –1.43 (–2.68 to –0.19) –0.48 (–2.07 to 1.12) 0.24
Leadership –0.84 (–2.20 to 0.52) –0.95 (–2.72 to 0.82) 0.54
Social skills –1.65 (–2.93 to –0.37) 0.00 (–1.64 to 1.65) 0.14
Composite scales
Externalizing problems 2.08 (0.74 to 3.42) 1.17 (–0.55 to 2.89) 0.01
Internalizing problems 1.07 (–0.36 to 2.50) 0.86 (–0.98 to 2.69) 0.21
Adaptive skills –1.19 (–2.45 to 0.08) –0.63 (–2.25 to 0.98) 0.12
BSI 1.60 (0.23 to 2.97) 1.46 (–0.30 to 3.21) 0.05
aIncludes subjects with F-scores of 0–1 and adjusted for race, educational level of the primary caretaker, marital status 
of the primary caretaker, urinary creatinine, and including sex–LMWP interaction term. All scales except conduct prob-
lems and leadership included 161 subjects. Conduct problems and leadership items are queried only on the 6- to 11-year 
BASC-PRS, so the number of subjects with these scales was 149.Prenatal phthalates and childhood behavior
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attention scale, which seemed to suggest a 
threshold effect at approximately 2 µM.
Even restricting our analyses to BASC 
surveys with F­scores < 2 (n = 161), most 
associations between phthalate exposure and 
behavior remain among boys. Significant 
sex–phthalate interactions (i.e., significant 
differences in the slope of the association 
between log­LMWP and behavior between 
girls and boys) were found for the aggres­
sion, conduct problems, hyperactivity, exter­
nalizing problems, and BSI. There were few 
significant associations among the girls; how­
ever, among boys, increasing log­LMWP 
metabolite concentrations were associated 
with poorer T­scores for aggression (β = 1.46; 
95% CI, 0.17–2.76), attention problems (β 
= 1.55; 95% CI, 0.22–2.88), and conduct 
problems (β = 2.79; 95% CI, 1.55–4.03), 
which was also significant in girls but with a 
smaller effect magnitude and less precision, 
externalizing problems (β = 2.08; 95% CI, 
0.74–3.42), and for the BSI (β = 1.60; 95% 
CI, 0.23–2.97) (Table 3).
Few surveys met the threshold scores for 
at risk or clinically significant (T­scores ≥ 60 
for the clinical and composite scales or ≤ 40 
for the adaptive scales) in this population. 
However, in a sensitivity analysis, we examined 
whether greater than the median metabolite 
concentration was associated with increased 
risk of scoring in the at­risk or clinically signif­
icant range on the scales identified in Table 2. 
In general, we found that the effects were in 
the same direction, although only attention 
problems (n = 27 at­risk or clinically signifi­
cant surveys) reached statistical significance 
(relative risk = 2.66; 95% CI, 1.06–6.66).
We also examined the metabolite­  specific 
effects on the BASC domains (Table 4). 
In general, we found consistency between 
the LMWP sum effects and the metabolite­
  specific models.
Except for aggression and conduct prob­
lems, the LMWP molar sum significance was 
replicated in at least two of the individual 
metabolite models for that scale. Although for 
monobutyl phthalate (MBP) only aggression 
and externalizing problems were statistically 
significant, the magnitude of the MBP asso­
ciations were very similar to the LMWP sum 
effects for attention problems, adaptability, 
and the BSI.
There were fewer consistent associations 
between LMWP metabolite concentra­
tions and executive functioning as measured 
with the BRIEF. However, similar to what 
was observed for the BASC, increased loge­
LMWP metabolite concentrations was asso­
ciated with poorer scores on the emotional 
control scale (β = 1.33; 95% CI, 0.18–2.49) 
and on the GEC index (β = 1.23; 95% CI, 
0.09, 2.36) (Table 5). There were no inter­
actions between phthalate exposure and the 
child’s sex for the BRIEF scales. We also com­
pared the   metabolite­specific models with 
the total LMWP molar sum (Table 6). There 
were a number of significant associations for 
monomethyl phthalate (MMP), however, 
this metabolite has the lowest concentration 
among all metabolites measured. MBP was 
associated with poorer scores on working 
memory (β = 1.53; 95% CI, –0.01 to 3.07), 
but in general, the molar sum effects were 
consistent in direction and magnitude with 
the metabolite specific effects.
Discussion
We report an association between prenatal 
exposure to LMWP and poorer parent­rated 
behavioral and executive functioning profiles 
for children between the ages of 4 and 9 years. 
Specifically, higher LMWP metabolite con­
centrations were associated with poorer scores 
on the aggression, attention problems, con­
duct problems, depression, and externalizing 
problems scales, and for the overall BSI on 
the BASC. Similarly, poorer executive func­
tioning was indicated by elevated scores on 
the emotional control scale and on the GEC 
index of the BRIEF. These effects remained 
statistically significant among boys, even after 
restricting the eligible surveys to those with 
F­scores of 0 or 1. All of these effects were 
consistent with a dose–response gradient.
In psychometric validity studies com­
paring the BRIEF and BASC (Gioia et al. 
2000), the BRIEF emotional control scale is 
strongly correlated (r > 0.6; p < 0.01) with the 
BASC­PRS aggression, anxiety, and depres­
sion scales (Gioia et al. 2000). Also in these 
validity studies, the GEC index is strongly 
correlated with the BASC­PRS aggression 
and attention problems scales. We find com­
parable associations among these measures, 
supporting the validity of our application of 
these instruments.
Taken as a whole, the profile of parent­
reported behaviors we find associated with 
prenatal LMWP metabolite concentrations is 
suggestive of the behavior profiles of children 
clinically diagnosed with disruptive behav­
ior disorders, for example, oppositional defi­
ant disorder, conduct disorder, or ADHD 
(Loeber et al. 2009; Reynolds and Kamphaus 
1998, Table 13.25) The strongest associa­
tions we find are for conduct problems, exter­
nalizing problems, and the BSI, and ratings 
on these parent­report scales typically serve 
as one element in a clinical diagnosis. The 
strong associations with the composite scales 
(externalizing and BSI) reflect the fact that 
on every scale for which a higher score reflects 
more problem behaviors, the direction of the 
association suggests an adverse effect of pre­
natal LMWP exposure. The association for 
the GEC on the BRIEF also reflects the con­
sistency in the direction of association on that 
instrument.
ADHD and disruptive behavior disorders 
are highly comorbid conditions, and no clini­
cal diagnosis can be based solely on screening 
instruments reliant on the parent’s percep­
tions and recollections of their child’s behav­
iors. The instruments we used include specific 
Table 5. Prenatal metabolite concentrations of LMWP and the BRIEF in a 
multiethnic birth cohort, Mount Sinai Medical Center, New York, New York, 
USA, 1998–2008.a
BRIEF scale/index β per loge-unit increase in LMWP (95% CI)
Inhibit 0.91 (–0.27 to 2.10)
Shift 0.61 (–0.59 to 1.81)
Emotional control 1.33 (0.18 to 2.49)
BRI 1.13 (–0.09 to 2.35)
Initiate 0.81 (–0.27 to 1.89)
Working memory 1.03 (–0.25 to 2.43)
Plan/organize 1.02 (–0.20 to 2.25)
Organization of materials 0.38 (–0.77 to 1.53)
Monitor 0.97 (–0.13 to 2.06)
MI 1.05 (–0.11 to 2.20)
GEC 1.23 (0.09 to 2.36)
aAdjusted for race, sex, educational level of the primary caretaker, marital status of 
the primary caretaker, and urinary creatinine. All scales except plan/organize included 
171 subjects. Plan/organize items are queried only on the 6- to 11-year BASC-PRS, so the 
number of subjects with these scales was 169.
Table 6. Comparison of betas from metabolite-specific models to the LMWP 
molar sum for the BRIEF in a multiethnic birth cohort, Mount Sinai Medical 
Center, New York, New York, USA, 1998–2008.
BRIEF scale/index LMWP sum   MBP MEP MiBP MMP
Inhibit 0.91 0.36 0.73 0.21 1.18
Shift 0.61 0.63 0.41 0.64 1.16
Emotional control 1.33* 0.79 1.10* 0.09 2.17*
BRI 1.13 0.67 0.89 0.30 1.77*
Initiate 0.81 0.77 0.68 0.83 1.56*
Working memory 1.03 1.53* 1.02 1.11 2.04*
Plan/organize 1.02 1.31 0.84 0.76 2.00*
Organization of materials 0.38 1.23 0.14 0.97 0.64
Monitor 0.97 0.45 0.75 0.26 1.20
MI 1.05 1.09 0.89 0.70 1.82*
GEC 1.23* 0.98 1.02 0.56 1.89*
Abbreviations: MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate. Adjusted for 
race, sex, educational level of the primary caretaker, marital status of the primary care-
taker, and urinary creatinine.
*p ≤ 0.05.Engel et al.
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items and patterns of responding to iden­
tify some types of parent reporting bias (e.g., 
excessive negativity), but other biases might 
go undetected. Parents’ perceptions are also 
based on behaviors occurring in family situa­
tions, whereas the child might show different 
behaviors at school, and parents might be 
unaware of the child’s subjective experiences 
of anxiety and other forms of internalization. 
Although few children in this study met the 
standard at risk or clinically significant criteria 
on the BASC­PRS, the patterns across scales 
and the consistency in findings across instru­
ments warrant additional study on the role of 
prenatal exposure to LMWP in the emergence 
of disruptive behavior problems in children.
The mechanism underlying a possible 
association between phthalates and neurode­
velopment has not been established, but may 
include prenatal disruption of the mater­
nal thyroid hormone system (Breous et al. 
2005; Hinton et al. 1986; Huang et al. 2007; 
Meeker et al. 2007; O’Connor et al. 2002; 
Pereira et al. 2007; Poon et al. 1997; Price 
et al. 1988; Sugiyama et al. 2005; Vermiglio 
et al. 2004) or activation of peroxisome pro­
liferator­activated receptors (Braissant and 
Wahli 1998; Corton and Lapinskas 2005; 
Latini et al. 2008; Peters et al. 2000) (Xu et al. 
2007). Early pregnancy mild hypothyroxine­
mia (normal thyroid­stimulating hormone, 
abnormal free T4) was found to be associated 
with abnormal motor and socialization quo­
tients in children at 18 months of age, which 
was preventable with early iodine supplemen­
tation (Berbel et al. 2009). Additionally, pre­
natal iodine­deficient hypothyroxinemia has 
been associated with ADHD in childhood 
(Vermiglio et al. 2004). However, additional 
research is needed to investigate these mecha­
nisms and determine their applicability to 
fetal and child neurodevelopment. We previ­
ously reported a relationship between prena­
tal urinary concentrations of some phthalate 
metabolites and neonatal behavior as meas­
ured by the Brazelton Neonatal Behavioral 
Assessment Scale (Engel et al. 2009). Here we 
extend those findings to behavior and execu­
tive functioning in childhood.
Direct child exposure to phthalates in 
the postnatal period may be independently 
associated with behavioral symptoms or may 
act cumulatively with prenatal exposure to 
increase risk. Recently, phthalate exposure 
during childhood was associated with ADHD 
in a cross­sectional study of Korean children 
between the ages of 8 and 11 years (Kim et al. 
2009). However, no previous study has exam­
ined the influence of prenatal exposure.
Although substantial attrition occurred 
during the 10 years since this cohort was 
recruited, we do not believe selection bias can 
account for our findings. For loss to follow­up 
to represent a bias in our study, phthalates 
would have to have a different relationship 
with behavior and executive functioning in 
the lost population. We carefully examined 
the characteristics of the full cohort (n = 404) 
and the follow­up cohort (n = 188) and found 
that the populations were quite similar, except 
for maternal age at enrollment (Table 1). This 
was expected, given that the youngest mothers 
tended to be more difficult to track using the 
contact information they provided and were 
also somewhat more likely to move out of 
the area shortly after delivery. However, there 
were no differences with respect to phthalate 
metabolite concentrations. Moreover, none of 
the mothers in our study were provided with 
their prenatal phthalate metabolite concen­
trations; therefore, their evaluation of their 
child’s behavior was not influenced by their 
own prenatal exposure level.
Exposure to phthalates is ubiquitous, and 
although phthalate biological activity may 
be less severe than that of other endocrine 
disruptors, the potential public health impact 
of exposure to phthalates might be greater. 
We report a pattern of associations between 
prenatal exposure to some LMWP and child­
hood behavior and executive functioning that 
is consistent with domains typically affected in 
childhood oppositional defiant disorder, con­
duct disorder, and ADHD. Additionally, most 
associations were consistent with a monotonic 
dose response. The reported relations between 
phthalates and thyroid hormone make such 
findings biologically plausible; however, addi­
tional research is urgently needed to replicate 
these findings and determine the underlying 
etiologic mechanism. Preventive measures to 
reduce exposure during pregnancy may be 
warranted should these findings be verified.
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